Methylene Blue
Methylthioninium chloride
Methylene Blue (Methylthioninium chloride) is a cognitive & mood research compound. Acts as an alternative mitochondrial electron carrier (boosts ATP) and antioxidant; nootropic at low doses. Note: it's an MAOI at higher doses — serotonergic-interaction caution.
Methylene Blue quick facts
| Reported research dose | 5mg-20mg |
| Route | Oral |
| Frequency | 1x Daily AM · 5 On 2 Off or Daily |
| Half-life | ~5–6 hrs |
| Forms | Oral |
| Evidence level | Human (clinical uses) + nootropic interest |
Low-dose only, and know the MAOI interaction if you're on any serotonergic meds. Respect it.
How Methylene Blue works
Acts as an alternative mitochondrial electron carrier (boosts ATP) and antioxidant; nootropic at low doses. Note: it's an MAOI at higher doses — serotonergic-interaction caution.
Proposed benefits
Low-dose mitochondrial ATP and antioxidant/nootropic support.
Where to get Methylene Blue
Buy Methylene Blue at Ion Peptide →The evidence for Methylene Blue
Graded by what exists behind each claim.
✅ Clinically validated
- An approved drug with over a century of use — it is first-line treatment for methemoglobinemia, with unambiguous clinical evidence, and is used as a surgical dye and in ifosfamide-induced encephalopathy.
- Cognitive and psychiatric trials exist and are small: work in bipolar depression and in memory tasks has reported benefit at low doses, but nothing approaching an approval-grade dataset.
📊 Correlative data
- Wide community use at low doses for cognitive and mitochondrial goals. Blue or green urine is universal and harmless. The consistently reported serious interaction is with serotonergic drugs.
🧪 Theoretical / extrapolated
- At low concentrations it acts as an alternative electron carrier in the mitochondrial transport chain, accepting electrons and donating them to cytochrome c — bypassing damaged complexes. At high concentrations it reverses and becomes a pro-oxidant.
- That hormetic dose-response is the whole story: the dose determines the direction of the effect, not just its size. It is also a potent MAO-A inhibitor, which is why the serotonin-syndrome risk with SSRIs is real and documented rather than theoretical.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Methylene Blue actually does
Methylene blue is a redox-cycling phenothiazinium dye whose entire personality flips with concentration, and almost every claim made about it is true at one dose and false at another. Its chemistry is a reversible two-electron couple: the blue oxidized form accepts electrons and becomes colorless leucomethylene blue, which gives them up again and turns blue. That single reaction is the antidote, the nootropic claim and the poison, depending only on how much is present and what is available to take the electrons.
At low concentration it acts as an artificial electron shuttle — and the experiment that shows this is more specific than the way it is quoted. In mitochondria with complex III inhibited, methylene blue bridged the block by reducing cytochrome c directly and improving membrane potential; the same work reported genuinely odd behavior, including decreased oxygen consumption on adding ADP, and found it qualitatively identical in rats, mice and guinea pigs Svab 2021. The bypass is at a particular point in the chain, and the paper that demonstrates it also documents that the respiratory response stops being normal. “Improves mitochondrial function” is not what that experiment says.
At therapeutic concentration it is a methemoglobin reductant, and the mechanism explains its own contraindication. NADPH methemoglobin reductase transfers electrons to methylene blue, producing leucomethylene blue, which then reduces ferric heme back to ferrous so the red cell can carry oxygen again Iolascon 2021. The NADPH comes from the pentose phosphate pathway, whose first and rate-limiting enzyme is glucose-6-phosphate dehydrogenase. Without G6PD, the reducing equivalents are not there, and methylene blue becomes a net oxidant instead — the drug flips from antidote to hemolytic agent, and the flip is a single enzyme.
And the pharmacology nobody prices in: it is a potent inhibitor of monoamine oxidase A. That is not a side note; it is the property behind the drug interaction that has produced real cases. MAO-A is the enzyme that clears serotonin, and inhibiting it in someone already taking a serotonergic drug is the standard setup for serotonin toxicity. An enzyme does not read the label; it responds to a concentration.
Cell, rodent, human — and where it stops
Step one, isolated mitochondria and rodents, where the electron bypass is real and narrow Svab 2021.
Step two, in humans — and this is the study that should be at the top of every methylene blue page, because it measured the thing the nootropic claim asserts and found the opposite. Investigators gave two doses of methylene blue and measured cerebral blood flow and metabolism, in humans and in rats, in the same paper. Both doses produced reductions in global cerebral blood flow, dose-dependently, in both species. In humans, the cerebral metabolic rate of oxygen fell; in rats, glucose metabolism fell. The authors describe the result as contrary to the hypothesized enhancement and raise a hormetic interpretation — that clinically relevant concentrations may sit on the wrong side of a biphasic curve Singh 2023. The compound is sold to raise brain energy. Measured in people, at doses in clinical use, it lowered brain blood flow and brain oxygen consumption.
Step three, the clinical uses that are real, so the page is not one-sided. Methylene blue is a genuine antidote for acquired methemoglobinemia, with an expert panel reaching greater than 75% agreement across the diagnostic and management questions Iolascon 2021, and it has an established vasoplegia role in critical care Elmati 2025. Those are settled uses at defined doses in monitored settings.
The obstacle, named. The hormetic argument is the whole difficulty. If the effect is biphasic — beneficial in a narrow low band, inverted above it — then the nootropic claim depends entirely on being in a window that has never been mapped in humans, and the one human measurement that exists was made above it Singh 2023. A dose window that has been asserted but not located is not a dose window.
Methylene Blue pharmacokinetics — how much of it actually gets in
The card says ~5–6 hours. The number is defensible and the shape of the curve matters more than the number.
What clears it. Methylene blue is reduced to leucomethylene blue in tissue, and the leuco form is conjugated — primarily by glucuronidation — and excreted in urine and bile. Renal clearance of the parent and its conjugates is why urine turns blue-green within hours of a dose, which is the most reliable, zero-cost pharmacokinetic readout in the whole Vault: it confirms absorption and rough timing without any assay. Some parent drug is also excreted unchanged.
The oral barrier. Oral absorption is substantial but incomplete and variable, with meaningful first-pass metabolism; the fraction reaching the systemic circulation as parent dye is well below unity, which is why intravenous dosing in the antidote setting uses much lower milligram figures than oral protocols. It also means an oral dose delivers a mixture of parent and leuco forms whose ratio nobody measures.
Numbers, and the tissue behavior that the plasma curve hides. The clinical antidote dose is milligrams per kilogram given by injection over minutes, and the response is visible within 30–60 minutes Iolascon 2021. The dye is highly tissue-distributed with a large apparent volume of distribution, so plasma concentration falls faster than tissue content — which is why a plasma half-life of a few hours coexists with urine that stays colored for a day or more. Exposure is measured in hours and tissue residence is measured in days, so dosing chosen to ‘keep levels up’ is answering the wrong question and stacking is how a low dose becomes a high one.
The comparator, and the reason it matters here. The intravenous route is the one every clinical dataset uses, and it is the route in the human cerebral blood flow study Singh 2023. An oral nootropic dose is being justified by intravenous clinical pharmacology with an unmeasured bioavailability factor in between. That factor is the difference between a low dose and a clinical one, and nobody selling oral methylene blue has published it.
What would have to be true, and how you would know it was not
Three predictions. The first is a screening test with a real mechanism behind it; the third is the one that argues against the product.
1. Anyone considering this should know their G6PD status first, and the mechanism says exactly why. Methylene blue's reduction requires NADPH from the pentose phosphate pathway, and G6PD is the rate-limiting enzyme of that pathway Iolascon 2021. Order G6PD once — it is a single, inexpensive, lifetime test. The falsifiable prediction if someone with G6PD deficiency takes it anyway: reticulocyte count rises and haptoglobin falls within days as hemolysis is compensated. That is the signature, it is orderable, and it is entirely preventable with one test that never needs repeating.
2. Urine color is the free confirmation, and its absence is informative. Blue-green urine within a few hours of an oral dose confirms absorption and gives a crude timing estimate. A urinalysis at baseline is worth having on file, because methylene blue interferes with several colorimetric dipstick readings and with pulse oximetry, and an interference mistaken for a result is its own hazard. Prediction: colored urine, an altered dipstick, and a falsely low pulse oximeter reading — all three are the dye, not the physiology.
3. The prediction that cuts against it: cognitive testing should show nothing, and the human imaging data says why. Two doses lowered global cerebral blood flow and the cerebral metabolic rate of oxygen in people Singh 2023. So run MoCA or a trail making test at baseline, at 4 weeks on, and 2 weeks after stopping. Prediction: no measurable gain, and any subjective improvement should not survive the two-week washout. If a real, repeatable gain does appear at a low oral dose, that is a genuine finding about the low end of a biphasic curve and it is currently unpublished in either direction.
What nobody has tested yet
Four things nobody has tested, and the first is the whole ballgame.
Nobody has mapped the hormetic curve in a human brain. The one human study measured two doses and both lowered cerebral blood flow and oxygen metabolism Singh 2023. If the low-dose claim is correct, there is a lower band where the direction reverses, and no published human imaging exists below the doses that were tested. That single dose-ranging study would either establish the nootropic use or end it.
Nobody has measured MAO-A inhibition at nootropic oral doses. The serotonin-toxicity risk is real enough that the prevalence of serotonergic co-medication in patients receiving perioperative methylene blue was worth a dedicated study McMillan 2025. What has never been quantified is the degree of MAO-A inhibition at a 5–20 mg oral dose — which is the number that would tell a person on an SSRI whether the risk applies to them or only to the surgical dose.
Nobody has published the oral bioavailability of a consumer-grade preparation. Every clinical number is intravenous. Without an oral-to-intravenous ratio, the phrase “low dose” has no defined meaning for the product people actually buy.
Nobody has checked whether the ADP anomaly appears in living tissue. The complex III study found decreased oxygen consumption on adding ADP — the opposite of normal respiratory control — in isolated mitochondria of three species Svab 2021. Whether that translates into an exercising human muscle is a measurable question with an obvious endpoint (VO2 at a fixed workload) and no data.
Methylene Blue — its own safety story, not its class's
This compound has two specific, mechanism-linked hazards and one interference problem. None of them is in the class block below.
Serotonin toxicity is the first, and it is not hypothetical. Methylene blue inhibits monoamine oxidase A. A published case describes serotonin syndrome after preoperative intrapulmonary methylene blue with intraoperative granisetron Huang 2022, and a cross-sectional study went looking for how often the setup exists at all — measuring the prevalence of serotonergic drug use in patients exposed to perioperative methylene blue McMillan 2025. The list of serotonergic drugs is long and ordinary: SSRIs, SNRIs, tricyclics, tramadol, triptans, dextromethorphan, ondansetron and granisetron. Anyone on any of those is in the interaction, and the enzyme does not distinguish a nootropic dose from a surgical one — only the concentration does, and nobody has measured it at oral doses.
G6PD deficiency is the second, and it inverts the drug. Reducing methemoglobin requires NADPH from the pentose phosphate pathway; without G6PD, methylene blue acts as an oxidant and causes hemolysis, which is why it is contraindicated in G6PD deficiency in the formal recommendations Iolascon 2021. G6PD deficiency is one of the commonest enzyme deficiencies in the world and is frequently undiagnosed. The single measure that reduces this risk to near zero is one test, once, before the first dose.
The interference problem, which is a safety issue in disguise. Methylene blue absorbs light at wavelengths pulse oximeters use, producing a falsely low saturation reading, and it colors urine and interferes with colorimetric assays. In a medical setting that can send clinicians chasing hypoxia that is not there. Anyone taking this should be able to say so in an emergency department, which is a reason for a written list rather than a warning.
The dose-inversion risk, stated plainly. At high concentration the same redox cycling that reduces methemoglobin generates it, so an overdose of the antidote causes the condition the antidote treats. Its established uses sit inside monitored settings at defined doses Elmati 2025, and the compound's therapeutic window is genuinely narrow. Sourcing matters more here than for almost anything else in the Vault: industrial and aquarium-grade methylene blue is not pharmaceutical grade and can carry heavy metal contamination, and there is no assay a buyer can run. This is education about mechanism, not a recommendation for use.
Sources read for this page
- Svab G, et al. Methylene Blue Bridges the Inhibition and Produces Unusual Respiratory Changes in Complex III-Inhibited Mitochondria. Studies on Rats, Mice and Guinea Pigs. Antioxidants (Basel) 2021 · PMID 33669457
- Singh N, et al. The effects of acute Methylene Blue administration on cerebral blood flow and metabolism in humans and rats. Journal of Cerebral Blood Flow and Metabolism 2023 · PMID 36803299
- McMillan E, et al. Prevalence of Serotonergic Drug Use in Patients Exposed to Perioperative Methylene Blue: A Cross-Sectional Study. Cureus 2025 · PMID 40271333
- Huang WH, et al. Postoperative Serotonin Syndrome Following Administration of Preoperative Intrapulmonary Methylene Blue and Intraoperative Granisetron: A Case Report. American Journal of Case Reports 2022 · PMID 35619329
- Iolascon A, et al. Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology 2021 · PMID 34467556
- Elmati PR, et al. Methylene blue in the critical care setting. World Journal of Critical Care Medicine 2025 · PMID 40880565
Methylene Blue — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Methylene Blue — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Methylene Blue moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Methylene Blue in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Methylene Blue
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | In G6PD deficiency methylene blue causes hemolysis. Check before, not after |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| hs-CRP (High-Sensitivity C-Reactive Protein) | General inflammatory baseline |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
Methylene Blue — frequently asked questions
What is Methylene Blue?
Methylene Blue (Methylthioninium chloride) is a cognitive & mood research compound. Acts as an alternative mitochondrial electron carrier (boosts ATP) and antioxidant; nootropic at low doses. Note: it's an MAOI at higher doses — serotonergic-interaction caution.
Is the full Methylene Blue protocol on this page?
The reported research dose is on this page, along with how Methylene Blue works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Methylene Blue?
Methylene Blue has an approximate half-life of ~5–6 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Methylene Blue?
Current evidence level: Human (clinical uses) + nootropic interest. Methylene Blue is offered for research purposes only and is not an approved medicine.
Methylene Blue inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Methylene Blue is used for
Methylene Blue appears under 4 goals in the goal router.
Related Cognitive & Mood compounds
Where this goes next
Methylene Blue is the cerebral metabolism arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.